

Neuromuscular Disorders Exome Requisition Form

The University of Chicago Genetic Services Laboratories 5841 South Maryland Avenue, Room G701/MC0077, Chicago, IL 60637

Toll Free: 888.824.3637 | Local: 773.834.0555 | Fax: 773.702.9130

ucgslabs@genetics.uchicago.edu | dnatesting.uchicago.edu | CLIA#: 14D0917593 | CAP#: 18827-49

Patient Information	
Gender: Male Female MRN:	Date of Birth: shkenazi Jewish Other
Ordering Physician Information REPORTING	G RESULTS: Reports will only be faxed out. Please check the boxes below for those who should receive by fax.
Referring Physician:	Genetic Counselor:
Phone: Fax:	Phone: Fax:
Email:	Email:
Referring Lab:	
Phone: Fax:	
Email:	
Indication for Testing ☐ Symptomatic:	REQUIRED INFORMATION. NECESSARY FOR TESTING [CD-10:
Results of previous genetic testing (including information on whether patient has	as been screened for SCA trinucleotide repeats):
Testing for known mutation/variant*: Gene Name:	Mutation/Variant:
	o Number: Relationship to Proband: or the Neuromuscular Disorders Exome: detailed clinic notes, pedigree, results of prior
Sample Information	
Date Sample Drawn:	
performed at a CLIA-certified laboratory. All samples should be shipped via over	Other: ultured cells. DNA samples are only accepted if the DNA extraction or isolation was rnight delivery at room temperature to the address at the top of this page. No weekend and date sample collected. Please see our website for other specimen requirements.
Ordering Checklist	For Office Use Only
Test Requisition Form (required)	
Completed Indication for Testing/ICD-10 study code (required)	
☐ Completed Clinical Checklist (required) ☐ Completed Billing Information (required)	
Completed Neuromuscular Disorders Consent Form (required)	
Completed Research Consent Form (recommended)	

Page 1 of 6 -1-



NEUROMUSCULAR DISORDERS CLINICAL CHECKLIST

REQUIRED

Please check all clinical features that apply, and use the additional space provided at the bottom of the form if needed

Neuromuscular disorder(s) present?	Other neurological findings present?	Biochemical testing performed?
YES (note age of onset below) NO	YES (see below) NO UNKNOWN	YES (see below) NO UNKNOWN
UNKNOWN	☐ Ataxia	Results of biochemical testing:
Age of onset:	☐ Dementia	☐ Elevated lactate:
Progressive neuromuscular disorder?	Dysarthria	☐ Elevated CK:
☐ YES☐ NO☐ UNKNOWN	Hyperreflexia	Normal results for the following tests:
Type of neuromuscular disorder	l — ··	
Myopathy	Hypotonia	Other:
With prominent contractures	☐ Seizures	
Details:	Spasticity	Cardiac findings present?
_	☐ Other:	1 — · · — —
Muscular dystrophy		YES (see below) UNKNOWN
Details:	Cognitive/developmental delays or	Cardiomyopathy
Congenital myasthenic syndrome	behavioral issues present?	Hypertrophic cardiomyopathy
Details:	YES (see below) NO UNKNOWN	
Peripheral neuropathy	Cognitive impairment	U Other – please specify:
Details:	Developmental regression	
☐ Other:	Global developmental delay	
Muscle biopsy performed?	☐ Mild ☐ Moderate ☐ Severe	Gastrointestinal (GI) issues present?
YES (see below) NO UNKNOWN		
Please specify results and attach copy of report:	Autism spectrum disorder	YES (see below) NO UNKNOWN
ricuse speemy results and attach copy of report.	☐ Behavioral / Psychiatric abnormality -	Please specify:
	please specify:	
	☐ Other:	Growth abnormality present?
Mitochondrial abnormality present?		YES (see below) NO UNKNOWN
☐ YES (see below) ☐ NO ☐ UNKNOWN	Brain MRI performed?	Please specify:
Please specify mitochondrial testing/results and	YES (see below) NO UNKNOWN	i lease specify.
attach copy of report:	Results of brain MRI:	Skeletal findings present?
	☐ No abnormalities identified	YES (see below) NO UNKNOWN
Floring and Alexander Control	Cerebellar hypoplasia	Please specify:
Electromyography/ Nerve Conduction	Migration defect (please specify)	i lease specify.
Velocity/ (EMG/NCV) performed?	wingration delect (please specify)	Neoplasms or immunodeficiency?
YES (see below) NO UNKNOWN	Lactate peak	
Results of EMG/NCV testing:		YES (see below) NO UNKNOWN
EMG	Other:	Please specify:
☐ No abnormalities detected	Cuanisfacial findings agreemed	
☐ Abnormal – please specify:	Craniofacial findings present?	Hearing/Vision
	YES (see below) NO UNKNOWN	YES (see below) NO UNKNOWN
NCV	Dysmorphic facies	☐ Vision abnormality – please specify
☐ No abnormalities detected	Please specify:	
Abnormal – please specify:		Hearing impairment – please specify
	Macrocephaly, HC:	agpaone product opposity
	Microcephaly, HC:	Other:
Family history of neuromuscular disorder	Other:	Other.
or other relevant findings?		
YES (see below) NO UNKNOWN	Cutaneous findings present?	
Please specify:	YES (see below) NO UNKNOWN	
	Please specify:	
Please inc	clude any additional relevant clinical informa	ation here:
	-	
In addition to this checklist, we strongly reco	mmend sending the following documentation wit	th the sample: detailed clinic notes, pedigree,
	results of prior genetic and metabolic testing.	



BILLING OPTIONS

All samples received with incomplete billing information will delay processing time.

Test cancelled while "in progress" will be billed for the amount of work completed up to that point.

Please note, we do not currently offer direct insurance billing for our Ataxia Exome.

Please forward all billing questions to: youtlaw@bsd.uchicago.edu or call (773-834-8220).

Patient Name: Last	First	(MI):	Date of Bir	th:
1.) Institutional Billing (Pre-payment is required for	r all samples referred from outs	ide the US or Canada.)		
Billing Institution:		PO#:		
Financial Contact:	Phon	e:	Fax:	
Address:	City:		State:	Zip:
Email (required):				
2.) Self-Pay We accept all major credit cards. Please call our office (in the control of the card) Important notice: We will not be responsible for refunding and the card with the ca	ny "cost differential" that may ontories' and invoice numbers to one of the contract of the cost of th	ensure proper receipt.) ss) 50 S. LaSalle Street go Wire Account No.: 28 me of Institution:	, Chicago, IL 60675 509	

We currently only offer institutional billing and self-pay for our Ataxia Exome. Insurance prior authorization is not absolutely mandatory before sending a sample to our laboratory. Insurance prior authorization services are offered as a courtesy and can be requested PRIOR to sending a sample to our laboratory (please see website for prior authorization request form). Samples received with appropriate billing information (institutional billing or self-pay) will be processed accordingly

Page 3 of 6 -3-



NEUROMUSCULAR DISORDER EXOME CONSENT FORM

University of Chicago Genetic Services Laboratories (UCGSL)

REQUIRED FOR EXOME TESTS

www.dnatesting.uchicago.edu

Patient Name:	 	_
Date of Birth:	 	
Overview		

Exome sequencing attempts to evaluate the coding regions of approximately 20,000 genes in the genome. This is called the 'exome'. The exome represents only 1.5% of the genome and comprises the majority of DNA variations that cause human disease. The UCGSL Neuromuscular Disorders Exome limits analysis of the exome sequencing data to a predefined set of 422 genes that have been associated with neuromuscular disease. For cases without a clearly pathogenic variant identified in the pre-defined list of genes, an additional analysis of previously reported pathogenic variants and truncating variants in known disease genes (present in the HGMD database) will be performed. The purpose of this test is to identify the underlying molecular basis of the specific neuromuscular disorder in the patient's family.

Accuracy

The analysis performed is specific to genes associated with neuromuscular disorders. Accurate interpretation of test results requires accurate and complete information regarding the patient's medical and family history. There is always a small possibility of an error or failure in sample analysis; this is always a possibility with complex testing in any laboratory. Extensive measures are taken to avoid these errors. The accuracy of genetic testing is limited by the methods employed, and sometimes by the nature of the condition for which testing is requested.

Limitations

Not all the exons in the genes being analyzed are targeted and captured due to certain inherent characteristics of the genome. Approximately 97-99% of exons are targeted in the diagnostic Exome tests. In addition, there is limited or no coverage in regions outside of the exome. Certain types of mutations are not detectable by this test, including trinucleotide repeat expansions, which are a common genetic cause of ataxia. This methodology will also not detect low level mosaicism and copy number variation mutations (i.e such as the deletion or duplication of an exon). Other types of rare genetic variation can interfere with this analysis. Pathogenic variants may be present in a region of a gene not covered by this test. Absence of findings for any particular gene does not mean that there are no pathogenic variants present in that gene. It is the responsibility of the referring physician, or a health care professional designated by the physician, to understand the limitations of the testing ordered, and to educate the patient regarding these limitations.

Testing & Analysis Pipeline

Of the thousands of variants identified by exome sequencing, a list of variants that are located within the predefined set of genes is generated. Most variants that are identified as part of exome sequencing will NOT undergo interpretation by a laboratory staff member. Only those variants identified that fall within a predefined gene and are considered to be potentially relevant to the patient's condition are reviewed by a team of Board-Certified PhD geneticists, MD geneticists, and genetic counselors who will determine the likelihood of the variant being related to the patient's disorder.

What is Reported?

UCGSL will report on genetic variants that have been reported to be pathogenic or predicted to be pathogenic or possibly pathogenic as well as unclassified variants in established genes on the pre-defined gene list.

What is Not Reported?

- Variants that occur in genes outside of the pre-defined gene list, unless they are clearly the cause of the patient's phenotype.
- Variants that occur in genes defined as medically actionable by the American College of Medical Genetics and Genomics (ACMG), unless those genes are also included on the pre-defined gene list.
- Carrier status for recessive disorders, with the exception of carrier status for genes that are included on the pre-defined gene list.
- Benign sequence changes not associated with disease, which are commonly identified in healthy people.
- Synonymous (silent) sequence changes not associated with a change in the amino acid.
- Variations associated with increased or decreased risk to develop common disorders (like high blood pressure) or involved in drug metabolism.
- Variations that have been associated with an increased risk for diseases that might present at an advanced age (like Alzheimer's Disease) in which there is no treatment or preventative measures.
- Pathogenic mutations and variants in genes with no current known association with disease.

Implication of Results

Because the implications of genetic testing results can be complex, involving both medical and emotional and social issues, results will only be reported through the referring physician or a professional designated by the physician, such as a genetic counselor. The issues associated with some types of genetic testing are particularly sensitive. Therefore, the laboratory reserves the right to provide testing only if genetic counseling can be provided.

Confidentiality

Results and patient information are confidential and will only be released to the referring physician, unless written consent for further distribution is provided or the laboratory directors are required by law to release this information. For patients within The University of Chicago affiliated centers, policy may require that reports are provided to the medical records department.

Consent for Neuromuscular Disorders Exome

I consent to the Neuromuscular Disorders Exome being performed on my sample, as requested by my healthcare provider. I understand that the genes and variants reviewed as part of exome analysis will be dependent on the test selected by my healthcare provider.

Signature of Patient/Parent /Legally Authorized Representative:	
Date:	
If Legally Authorized Representative please describe relationship to individual	:
Referring Clinician By signing this consent form, the referring clinician 1) indicates that this cons form has been reviewed with the patient and/or the patient's parent or guard and 2) accepts responsibility for pre- and post- test genetic counseling.	
Signature of Referring Clinician:	

Page 4 of 6 -4-



RESEARCH CONSENT FORM – The University of Chicago

The Division of Biological Sciences | University of Chicago RECOMMENDED BUT OPTIONAL

CONSENT/AUTHORIZATION BY SUBJECT FOR PARTICIPATION IN A RESEARCH PROTOCOL FOR THE BETTER UNDERSTANDING OF THEIR GENETIC CONDITION

Protocol Number: 11-0151

Name of Subject :	 	
Date of Birth:		

STUDY TITLE: Molecular Genetic Studies of Rare Orphan Genetic Disease

Research Team: Soma Das, Ph.D.

5841 S. Maryland Ave. Room L-155 MC 0077, Chicago, IL 60637

773-834-0555

You are being asked to allow your child to participate in a research study that may help us learn more about the genetic condition for which you are being tested. This consent form describes the study, the risks and benefits of participation, as well as how your confidentiality will be maintained. Please take your time to contact us with questions and feel comfortable making a decision whether to participate or not. If you decide to participate in this study, please sign this form. Throughout this consent form, "you" will refer to you or your child, as appropriate.

WHY IS THIS STUDY BEING DONE?

You have already consented to clinical genetic testing. We are asking you to also participate in further studies. The purpose of these studies is to learn more about the genetic cause of diseases tested for in our lab, gather more information about these disorders, and experiment with new methods that may be better for testing.

WHAT IS INVOLVED IN THE STUDY?

During this study, Dr. Das and her team will collect information about you for this research. We may contact your doctor to request additional Protected Health Information (PHI), which consists of any health information related to your diagnosis (such as date of birth, medical record number, primary diagnosis, clinical features, relevant and family history, outcome). The data collected will be used to develop a database of patients being tested for genetic diseases and will be kept for the duration of the database. This study will look at how often different genetic mutations happen and clinical information related to the mutation.

When our lab is researching new genes or testing methods that are related to your diagnosis, we may include your sample, with others from similar patients in a small study before offering this new test. This data will help in directing doctors about the likelihood of a positive or negative test result in their patient. We may also use your sample to set up new methods that will improve the clinical testing in our

laboratory. Your clinical information and sample, without any identifiers, may also be shared with other researchers that are interested in this specific condition.

HOW LONG WILL I BE IN THE STUDY?

Once enrolled, you will likely remain in this study as long as your DNA sample remains in our laboratory. If you want your sample, to be removed from the study at any time, please contact us, and the sample will not be used for further studies. Existing results will remain in our database until the study ends.

WHAT ARE THE RISKS OF THE STUDY?

There are no known added risks of the research. No additional information will be obtained from you, as all of the information has already been collected as part of clinical genetic testing or evaluation by your doctor.

ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY?

If you agree to take part in this study, there may be direct medical benefit to your family. We may identify a cause for the genetic disease in your family. If a mutation is identified in your DNA, through our testing, your referring doctor will be notified and will receive a clinical report. Our study may also be helpful in finding the genetic causes of disease and will benefit doctors and patients as a group.

WHAT OTHER OPTIONS ARE THERE?

You may choose not to participate.

WHAT ARE THE COSTS?

There will be no additional costs to you or your insurance company resulting from this research study. However, you or your insurance company will be responsible for costs related to your usual medical care.

WILL I BE PAID FOR MY PARTICIPATION?

You and your child will not be paid to participate.

WHAT ABOUT PRIVACY?

Study records that identify you will be kept private. All of your personal information will be entered into a password-protected database to prevent access to non-authorized personnel. If your data is shared with other researchers, all patient identifiers will be removed. Data from this study may be used in medical journals or presentations. If results from this study or related studies are made public in a medical journal, individual patients will not be identified. If we wish to use a patient's identity in a medical journal, we will ask for your permission at that time.

As part of the study, Dr. Das and her team will report any positive results of further testing to your referring doctor and/or genetic counselor. Dr. Das may also share these results, without your name or date of birth, with other researchers.

Page 5 of 6 -5 -



RESEARCH CONSENT FORM – The University of Chicago

The Division of Biological Sciences | University of Chicago RECOMMENDED BUT OPTIONAL

People from the University of Chicago, including the Institutional Review Board (IRB), a committee that oversees research at the University of Chicago, may also view the records of the research. If health information is shared outside the University of Chicago, the same laws that the University of Chicago must obey may not protect your health information. Dr. Das does not have to give you any results that are not are not important to your health or your family's health at that time.

This consent form will be kept by the research team for at least six years. The study results will be kept in your child's research record and be used by the research team indefinitely. When the study ends, your personal information will be removed from all results. Any information shared with your doctor may be included in your medical record and kept forever.

The Genetic Information Nondiscrimination Act (GINA) is a federal law that may help protect you from health insurance or employment discrimination based on genetic information. GINA is a federal law that will protect you in the following ways:

- Health insurance companies and group plans may not request genetic information from this research;
- Health insurance companies and group plans may not use your genetic information when making decisions regarding your eligibility or premiums;
- Employers with 15 or more employees may not use your genetic information when making a decision to hire, promote, or fire you or when setting the terms of your employment.

GINA does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance. GINA also does not protect you against discrimination based on an already-diagnosed genetic condition or disease.

WHAT ARE MY RIGHTS AS A PARTICIPANT?

Taking part in this study is optional. You may choose not to participate at any time during the study. Choosing not to participate or leaving the study will not affect your child's testing at the University of Chicago.

If you choose to leave the study and you do not want any of your child's future health information to be used, you must inform Dr. Das in writing at the address on the first page. Dr. Das may still use your child's information that was collected before to your written notice. You will be given a signed copy of this form. This consent form does not have an expiration date.

WHO DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?

If you have further questions about the study, please call 773-834-0555.

If you have any questions about your rights in this research study you may contact the IRB, which protects participants in research projects. You may reach the Committee office between 8:30 am and 5:00 pm, Monday through Friday, by calling (773) 702-6505 or by writing: University of Chicago, Institutional Review Board, 5841 S. Maryland Ave., MC7132, I-625, Chicago, IL 60637.

Consent

I have received information about this research project and the procedures. No guarantee has been given about possible results. I will receive a signed copy of this consent form for my records.

I give my permission to participate in the above research project.

Signature of Subject:
Date:
I give my permission for my child/relative/the person I represent to participate in the above research project.
Signature of Parent / Legal Guardian / Legally Authorized Representative:
Date:

Page 6 of 6 - 6 -